Gapping up
In reaction to strong earnings/guidance: .
M&A news: THS +5.1% (to acquire Flagstone Foods for $860 mln), PPG +2.9% (reaches agreement to acquire Comex; transaction is valued at $2.3), PHG +2.7% (announced that it will start the process to combine its Lumileds and Automotive lighting businesses into a stand-alone company within the Philips Group; will explore strategic options to attract capital from third party investors for this business), CNSL +2.2% (co and Enventis (ENVE, formerly HTCO) to merge).
Other news: DRNA +13.5% (researchers demonstrate promise of Dicerna investigational therapy in preclinical model of primary Hyperoxaluria Type 1), MNKD +11.9% (announces FDA approval of AFREZZAn for the treatment of Diabetes), FLML +7.4% (announces FDA approval of VAZCULEP), GRH +6.4% (announces multiple pipeline project in Pennsylvania and West Virginia; total capacity of 270,000 barrels per day), SREV +6.2% (Altai Capital Management discloses 9.9% active stake in 13D filing), CHCI +5.2% (enters into option agreement allowing repurchase of shares held by former Chief Operating Office), LBMH +5.1% (still checking), GPRO +4.7% (cont vol following IPO last week), ALIM +4.2% (Iluvien receives positive outcome of repeat-use procedure for 10 additional European countries), IDTI +3.7% (positive comments by Jon Najarian on Friday), EVAR +3.6% (initiated with a Outperform at Credit Suisse), AUO +2.5% (still checking), NTAP +2.3% (positive Barron's mention), IP +2.2% (positive Barrons mention), KPTI +1.5% (underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 397,087 shares of its common stock at a price of $42.50/share before underwriting discounts), MPEL +1.4% (Gambling insurance in China is now prohibited, according to reports), AMPE +1.1% (initiates study of multiple injections of Ampion into the knees of patients with oa of the knee to assess its healing and cartilage regeneration effects), .
Analyst comments: GWPH +5.1% (target raised to $147 from $97 at Piper Jaffray; Overweight), AMED +2.7% (upgraded to Hold from Sell at Deutsche Bank), MILL +2% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), UTEK +2% (upgraded to Buy at Noble Financial), YHOO +1.3% (upgraded to Overweight from Neutral at Piper Jaffray), KLAC +1.1% (upgraded to Buy from Neutral at B. Riley & Co), WTSL +1.1% (upgraded to Neutral from Sell at B. Riley & Co), FINL +1% (target raised to $35 from $33 at Monness Crespi & Hardt), MU +1% (added to Focus List at Credit Suisse)